Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP3K12 | Q12852 | 6/20 | 0.39 |
| ▸ | HDAC1 | Q13547 | 4/20 | 0.36 |
| ▸ | BTK | Q06187 | 5/20 | 0.35 |
| ▸ | CYP2C8 | P10632 | 1/20 | 0.34 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.34 |
| ▸ | MAP3K13 | O43283 | 2/20 | 0.34 |
| ▸ | SLC6A7 | Q99884 | 1/20 | 0.33 |
| ▸ | CCR2 | P41597 | 2/20 | 0.32 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11963315 | 0.84 | SLC6A7 (0.38) | MAP3K12HDAC1BTKCYP2C8KCNH2 | |
| SCHEMBL11963491 | 0.84 | HDAC1 (0.35) | MAP3K12HDAC1BTKCYP2C8KCNH2 | |
| SCHEMBL12818162 | 0.81 | CCR2 (0.46) | MAP3K12CCR2 | |
| SCHEMBL1704892 | 0.76 | KDM4E (0.40) | MAP3K12BTKCYP2C8KCNH2SLC6A7 | |
| SCHEMBL11963547 | 0.75 | ELANE (0.40) | MAP3K12HDAC1BTKCYP2C8KCNH2 | |
| SCHEMBL16872560 | 0.74 | CHRNB2 (0.56) | MAP3K12HDAC1 | |
| SCHEMBL2723382 | 0.74 | CHRNB2 (0.56) | MAP3K12HDAC1 | |
| SCHEMBL2226606 | 0.72 | PBRM1 (0.53) | HDAC1BTKCYP2C8KCNH2SLC6A7 | |
| SCHEMBL4823374 | 0.72 | PBRM1 (0.53) | HDAC1BTKCYP2C8KCNH2SLC6A7 | |
| SCHEMBL12817788 | 0.72 | CCR2 (0.54) | CCR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7115597-B2 | Tyrosine kinase inhibitors | MERCK & CO., INC. (US) | 2006-10-03 | — | — | US | disclosed |
| US-20040063720-A1 | Tyrosine kinase inhibitors | MERCK & CO., INC. | 2004-04-01 | — | — | US | disclosed |
| US-20020137755-A1 | Tyrosine kinase inhibitors | BILODEAU MARK T (US) | 2002-09-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020137755-A1 | Tyrosine kinase inhibitors | ERBB2, TYRO3, TIE1 | MAP3K12 30/4885HDAC1 2005/4885BTK 25/4885 |
| US-20040063720-A1 | Tyrosine kinase inhibitors | ERBB2, TYRO3, TIE1 | MAP3K12 30/4885HDAC1 2005/4885BTK 25/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.